Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PD-L1 is a transmembrane protein that plays a crucial role in suppressing the adaptive immune system. By binding to its receptor PD-1 on T cells, PD-L1 transmits an inhibitory signal, reducing T-cell proliferation and cytokine production. This pathway is important for preventing autoimmunity but can be exploited by tumors to evade immune surveillance, making it a major target for cancer immunotherapy.
Inhibition of PD-1 signaling by blocking PD-L1 binding, leading to enhanced T-cell activation and anti-tumor immunity. Recruitment of phosphatases such as SHP-2 via the Immunoreceptor Tyrosine-Based Switch Motif (ITSM) in PD-1 after ligand binding.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Programmed Cell Death Ligand 1 (PD-L1).